Evidence map›Paper›PMID 33843025›Full record

ArticleAnnals of surgical oncology2021

Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.

Makoto Sohda, Hiroshi Saeki, Hiroyuki Kuwano, Tatsuya Miyazaki, Takehiko Yokobori, Akihiko Sano, Makoto Sakai, Yoshihiro Kakeji, Yasushi Toh, Yuichiro Doki and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Makoto SohdaDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan. msohda@gunma-u.ac.jp.
Hiroshi SaekiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Hiroyuki KuwanoDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Tatsuya MiyazakiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Takehiko YokoboriDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Akihiko SanoDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Makoto SakaiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Yasushi TohDepartment of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Hisahiro MatsubaraDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Gunma University · JPChiba University · JPKobe University · JPNational Hospital Organization Kyushu Cancer Center · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal neuroendocrine carcinoma (ENEC) has a poor prognosis, and predicting the prognosis by examining various markers may contribute to the determination of treatment strategies. Therefore, a multiple-institution retrospective study was performed to identify biomarkers using diagnostic immunohistochemistry and serum tumor markers that predict the prognosis of patients with ENEC.

methodsThe results of immunohistochemical examination and serum tumor markers were extracted from the data of 141 ENEC patients at 39 institutions certified by the Japan Esophageal Society. The study then examined correlations between these data and prognosis or treatment effects.

resultsThe ENEC patients with positively for all expression of synaptophysin (Syn), chromogranin A (CgA), and CD56 had a significantly worse prognosis than the patients with other expression patterns. Additionally, surgery and chemoradiotherapy were significantly more effective treatments than chemotherapy for the patients who were not positive for all expressions of Syn, CgA, and CD56. In terms of serum tumor markers, the patients with a high neuron-specific enolase (NSE) value had a significantly worse prognosis than the patients with a normal NSE value, and complete response (CR) cases treated with chemotherapy were significantly fewer in the high-NSE group. The results of multivariate analysis demonstrated that high NSE levels were an independent poor prognostic factor for esophageal endocrine cell carcinoma.

conclusionThis study showed that positivity for all expressions of Syn, CgA, and CD56, and a high NSE value were significantly worse prognostic factors for ENEC patients than other expression patterns and may be important prognostic biomarkers of ENEC.

Indexed as

Carcinoma, NeuroendocrineNeuroendocrine CellsBiomarkers, TumorChromogranin AHumansPrognosisRetrospective StudiesBiomarkers, TumorChromogranin A

Identifiers

PMID33843025
OpenAlexW3154244738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.